CLINICAL_TRIALS
trial_result
· 2020-09-29
Clinical Trial Update: A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU). [Phase 2]
Summary
Phase 2 trial update for GDC-0853 in refractory chronic spontaneous urticaria (CSU) has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genentech, Inc. | Conditions: Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2020-09-29